News Focus
News Focus
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

Re: Democritus_of_Abdera post# 1963

Saturday, 06/07/2008 10:17:16 PM

Saturday, June 07, 2008 10:17:16 PM

Post# of 2446
Thanks, DoA, for the webcast annotations and hyperlinks.

>…those interested in siRNA as an anti-VEGF therapy may be interested in the comments concerning AGN-745 [a.k.a. Sirna-027] albeit they were characteristically brief.<

The comments were notable in their omission of any information of consequence. In fact, in the almost three years since AGN inked its AMD deal with Sirna Therapeutics (#msg-7926760), AGN has probably devoted less than five minutes in total to discussing this program.

I think it’s reasonable to infer that standalone Sirna-027 doesn’t work well enough to form the basis of a commercial AMD program in the Lucentis era.

Moreover, I think we can probably put to rest the notion that MRK is thinking of marrying Sirna-027 to I-vation. Here’s what I said about this a year ago (#msg-20924124):

>>
…MRK could yet be interested in marrying Sirna-027 to I-vation. Investors have a simple way to track this: If MRK does not make a move to buy out AGN’s interest in Sirna-027 fairly soon, it almost certainly means that MRK is not contemplating a Sirna-027+I-vation combination.

<<

Regards, Dew

p.s. I thought the most promising program from a commercial standpoint that AGN talked about was the one using Lumigan to enhance eyelashes: #msg-29857899.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRDX News